Rats were trained to discriminate between the effects of 0.6 mg/kg of (+)-amphetamine given intraperitoneally saline in a two-lever operant task, according to a fixed ratio ( FR10 ) schedule of food reinforcement. Once trained (greater than 90% responding on the appropriate lever during sessions with drug and saline, respectively over 2 weeks), they were given tests of generalization with various type A, type B or mixed type monoamine oxidase inhibitors (MAOI). Generalization was tested during the first 100 sec of a 15 min trial during which no reinforcements were given (extinction) followed by reinforcement on both levers for the rest of the session. Generalization to amphetamine was estimated using both the percentage of responding on the "drug lever" and a measure of choice of lever. None of the type A MAOI's tested [ cimoxatone (MD 780515), clorgyline, LY 51641, moclobemide (Ro 11-1163), toloxatone] showed generalization towards the lever for amphetamine. Clear or partial amphetamine-like responding was observed with the B type MAOI (+/-)-deprenyl and LY 54761 but not with two other type B MAOI's MD 240928 or pargyline. (+/-)-Tranylcypromine, but not nialamide (mixed type MAOI's), induced dose-dependent responding on the lever for amphetamine. It was concluded that amphetamine-like activity was not an intrinsic property of A or B type MAOI's.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0028-3908(84)90031-5DOI Listing

Publication Analysis

Top Keywords

type maoi's
16
mixed type
12
type
9
monoamine oxidase
8
lever amphetamine
8
discrimination amphetamine
4
amphetamine cue
4
cue effects
4
effects mixed
4
type inhibitors
4

Similar Publications

Targeting monoamine oxidases in cancer: advances and opportunities.

Trends Mol Med

October 2024

Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA 99223, USA. Electronic address:

Monoamine oxidases (MAOs) are a crucial pair of isoenzymes responsible for degrading monoamine neurotransmitters and dietary amines. In addition to extensive studies of their roles in the context of brain functions and disorders over decades, emerging evidence indicates that MAOs are also often dysregulated and associated with clinical outcomes in diverse cancers, with the ability to differentially regulate cancer growth, invasion, metastasis, progression, and therapy response depending on the cancer type. In this review, we summarize recent advances in understanding the clinical relevance, functional importance, and mechanisms of MAOs in a broad range of cancers, and discuss the application and therapeutic benefit of MAO inhibitors (MAOIs) for cancer treatment, highlighting the roles of MAOs as novel regulators, prognostic biomarkers, and therapeutic targets in cancer.

View Article and Find Full Text PDF

Inhibition of Monoamine Oxidases by Pyridazinobenzylpiperidine Derivatives.

Molecules

June 2024

Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi 682041, India.

Monoamine oxidase inhibitors (MAOIs) have been crucial in the search for anti-neurodegenerative medications and continued to be a vital source of molecular and mechanistic diversity. Therefore, the search for selective MAOIs is one of the main areas of current drug development. To increase the effectiveness and safety of treating Parkinson's disease, new scaffolds for reversible MAO-B inhibitors are being developed.

View Article and Find Full Text PDF

Efficacy of Pharmacotherapies for Bulimia Nervosa: A Systematic Review and Meta-Analysis.

Focus (Am Psychiatr Publ)

July 2024

Center for Rehabilitation Medicine, Department of Psychiatry, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China (Yu, Shao); The Second Clinical Medical College of Zhejiang, Chinese Medicine University, Hangzhou, Zhejiang, China (Zhang); Hangzhou Xiaoshan No 2 People's Hospital, Hangzhou, Zhejiang, China (Shen).

Objective: The main purpose was to evaluate the efficacy and tolerability of different medications used to treat bulimia nervosa (BN).

Methods: Randomized controlled trials (RCTs) were identified from published sources through searches in PubMed, Cochrane Library, Web of Science, and Embase from inception to November 2022. Primary outcomes were changes in the frequency of binge eating episodes and vomiting episodes from baseline to endpoint.

View Article and Find Full Text PDF

Efficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis.

BMC Pharmacol Toxicol

December 2023

Center for Rehabilitation Medicine, Department of Psychiatry, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.

Objective: The main purpose was to evaluate the efficacy and tolerability of different medications used to treat bulimia nervosa (BN).

Methods: Randomized controlled trials (RCTs) were identified from published sources through searches in PubMed, Cochrane Library, Web of Science, and Embase from inception to November 2022. Primary outcomes were changes in the frequency of binge eating episodes and vomiting episodes from baseline to endpoint.

View Article and Find Full Text PDF

Sizes and ligands tuned gold nanocluster acting as a new type of monoamine oxidase B inhibitor.

Biosens Bioelectron

October 2021

College of Pharmacy, Jinan University, Guangzhou, 510632, PR China; First Affiliated Hospital of Jinan University, Guangzhou, 510632, PR China. Electronic address:

Monoamine oxidase inhibitors (MAOIs) are a class of drugs that can be used in the treatment of Parkinson's disease, clinical depression, and anxiety by targeting monoamine oxidase B (MAO). However, the side effects of MAOIs drive the requirement of a new framework of enzyme inhibitors development. In this context, a new type of MAOI has been built on the framework of gold nanoclusters (AuNCs), realizing the transformation from no function of small molecules to MAOI function of ligand-modified AuNCs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!